Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia

M. Imran Aslam, Anthony P. Cardile, George E Crawford

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.

Original languageEnglish (US)
Pages (from-to)22-23
Number of pages2
JournalJournal of the International Association of Providers of AIDS Care
Volume13
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Thrombopoietin Receptors
Peptide Receptors
Thrombocytopenia
HIV
Immunoglobulin D
Retreatment
Intravenous Immunoglobulins
Therapeutics
Complementary Therapies
Adrenal Cortex Hormones
Safety
romiplostim

Keywords

  • HIV
  • peptide thrombopoietin receptor agonist
  • primary HIV-associated thrombocytopenia
  • romiplostim
  • thrombocytopenia

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases

Cite this

Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia. / Aslam, M. Imran; Cardile, Anthony P.; Crawford, George E.

In: Journal of the International Association of Providers of AIDS Care, Vol. 13, No. 1, 01.2014, p. 22-23.

Research output: Contribution to journalArticle

@article{a4d5dfc958b54e5cbf96c77ac9f6f0a9,
title = "Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia",
abstract = "Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.",
keywords = "HIV, peptide thrombopoietin receptor agonist, primary HIV-associated thrombocytopenia, romiplostim, thrombocytopenia",
author = "Aslam, {M. Imran} and Cardile, {Anthony P.} and Crawford, {George E}",
year = "2014",
month = "1",
doi = "10.1177/2325957413502539",
language = "English (US)",
volume = "13",
pages = "22--23",
journal = "Journal of the International Association of Providers of AIDS Care",
issn = "2325-9574",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia

AU - Aslam, M. Imran

AU - Cardile, Anthony P.

AU - Crawford, George E

PY - 2014/1

Y1 - 2014/1

N2 - Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.

AB - Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.

KW - HIV

KW - peptide thrombopoietin receptor agonist

KW - primary HIV-associated thrombocytopenia

KW - romiplostim

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84893081217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893081217&partnerID=8YFLogxK

U2 - 10.1177/2325957413502539

DO - 10.1177/2325957413502539

M3 - Article

C2 - 24036490

AN - SCOPUS:84893081217

VL - 13

SP - 22

EP - 23

JO - Journal of the International Association of Providers of AIDS Care

JF - Journal of the International Association of Providers of AIDS Care

SN - 2325-9574

IS - 1

ER -